Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy

被引：2
|
作者：
Cooper, Lauren B. [1 ,2 ]
Hernandez, Adrian F. [2 ]
机构：
[1] Inova Heart & Vasc Inst, Falls Church, VA USA
[2] Duke Univ, Med Ctr, Durham, NC USA
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2018年 / 20卷 / 08期
关键词：
HEART-FAILURE; HYPERKALEMIA; SPIRONOLACTONE; MORTALITY; ASSOCIATION;
D O I：
10.1002/ejhf.1221
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1227 / 1229
页数：3
相关论文
共 50 条
  • [31] Monitoring renal safety in mineralocorticoid receptor antagonist trials
    Zannad, Faiez
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (04) : 466 - 468
  • [32] Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
    Shah, Monarch
    Awad, Alaa S.
    Abdel-Rahman, Emaad M.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [33] Stereochemical Requirements for the Mineralocorticoid Receptor Antagonist Activity of Dihydropyridines
    Arhancet, Graciela B.
    Woodard, Scott S.
    Dietz, Jessica D.
    Garland, Danny J.
    Wagner, Grace M.
    Iyanar, Kaliappan
    Collins, Joe T.
    Blinn, James R.
    Numann, Randal E.
    Hu, Xiao
    Huang, Horng-Chih
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (10) : 4300 - 4304
  • [34] Implication of Mineralocorticoid Receptor Antagonist Esaxerenone in Patients with HFpEF
    Imamura, T.
    Oshima, A.
    Kinugawa, K.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (04): : S438 - S439
  • [35] Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist
    McManus, Frances
    McInnes, Gordon T.
    Mc Connell, John
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (01): : 44 - 52
  • [36] Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure
    Cooper, Lauren B.
    Hammill, Bradley G.
    Peterson, Eric D.
    Pitt, Bertram
    Maciejewski, Matthew L.
    Curtis, Lesley H.
    Hernandez, Adrian F.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2017, 10 (01):
  • [37] Resistant Hypertension Mineralocorticoid Receptor Antagonist or Renal Denervation?
    Carey, Robert M.
    HYPERTENSION, 2016, 67 (02) : 278 - 280
  • [38] Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist
    Frances McManus
    Gordon T McInnes
    John MC Connell
    Nature Clinical Practice Endocrinology & Metabolism, 2008, 4 : 44 - 52
  • [39] The mineralocorticoid receptor antagonist spironolactone enhances morphine antinociception
    Lilius, T. O.
    Jokinen, V.
    Neuvonen, M. S.
    Vaananen, A. J.
    Niemi, M.
    Rauhala, P. V.
    Kalso, E. A.
    EUROPEAN JOURNAL OF PAIN, 2014, 18 (03) : 386 - 395
  • [40] Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure
    Cooper, Lauren B.
    Hammill, Bradley G.
    Peterson, Eric D.
    Pitt, Bertram
    Maciejewski, Matthew L.
    Curtis, Lesley H.
    Hernandez, Adrian F.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (18): : 1973 - 1975
12345